Table 2 The network meta-analysis results of all outcomes
Outcomes | DC | MDC | MDCI |
|---|---|---|---|
Overall survival (HR (95% CrI)) | |||
 DC | 1 | 1.20 (0.71, 2.43) | 1.71 (1.47, 6.42) |
 MDC | 0.81 (0.42, 1.44) | 1 | 1.32 (1.04, 4.35) |
 MDCI | 0.60 (0.16, 0.92) | 0.74 (0.23, 0.87) | 1 |
Progression-free survival (HR (95% CrI)) | |||
 DC | 1 | 1.12 (0.74, 1.75) | 1.11 (0.63, 2.2) |
 MDC | 0.91 (0.60, 1.45) | 1 | 1.04 (0.67, 1.7) |
 MDCI | 0.88 (0.46, 0.98) | 0.97 (0.59, 1.51) | 1 |
Total severe adverse events (OR (95% CrI)) | |||
 DC | 1 | 0.56 (0.42, 0.76) | 0.73 (0.44, 0.97) |
 MDC | 1.17 (0.64, 2.10) | 1 | 0.82 (0.42, 1.64) |
 MDCI | 4.69 (2.79, 7.87) | 2.64 (1.73, 4.05) | 1 |
Leukopenia (OR (95% CrI)) | |||
 DC | 1 | 0.45 (0.32, 0.74) | 0.85 (0.54, 1.27) |
 MDC | 1.25 (0.64, 3.15) | 1 | 0.52 (0.12, 0.85) |
 MDCI | 6.69 (4.79, 9.87) | 2.14 (1.33, 4.45) | 1 |
Thrombocytopenia (OR (95% CrI)) | |||
 DC | 1 | 0.76 (0.34, 0.89) | 0.72 (0.41, 1.17) |
 MDC | 2.74 (1.64, 3.10) | 1 | 0.78 (0.39, 1.53) |
 MDCI | 3.14 (2.65, 7.75) | 2.52 (1.85, 3.45) | 1 |
RBC transfusion (OR (95% CrI)) | |||
 DC | 1 | 0.63 (0.31, 0.96) | 0.69 (0.38, 1.54) |
 MDC | 2.24 (0.67, 2.85) | 1 | 0.78 (0.51, 2.44) |
 MDCI | 4.69 (2.79, 7.87) | 2.64 (1.43, 4.05) | 1 |
PLT transfusion (OR (95% CrI)) | |||
 DC | 1 | 0.57 (0.32, 0.63) | 0.77 (0.54, 1.63) |
 MDC | 1.25 (1.03, 2.18) | 1 | 0.75 (0.38, 1.75) |
 MDCI | 4.41 (3.14, 5.17) | 1.64 (1.03, 3.15) | 1 |
G-CSF (OR (95% CrI)) | |||
 DC | 1 | 0.36 (0.22, 0.85) | 0.71 (0.34, 1.57) |
 MDC | 1.43 (0.74, 3.10) | 1 | 0.81 (0.62, 1.79) |
 MDCI | 3.69 (2.72, 5.87) | 2.94 (1.85, 3.74) | 1 |
Hospitalization (OR (95% CrI)) | |||
 DC | 1 | 0.46 (0.42, 0.76) | 0.69 (0.44, 2.17) |
 MDC | 1.10 (0.68, 2.85) | 1 | 0.76 (0.31, 1.54) |
 MDCI | 5.64 (2.92, 7.52) | 1.38 (0.26, 3.25) | 1 |